Drug-releasing stent with ceramic-containing layer

ABSTRACT

A vascular or endoluminal stent is adapted to be implanted in a vessel, duct or tract of a human body to maintain an open lumen. The stent includes a base layer of a biologically compatible metal. An intermediate metal particle layer of substantial greater radiopacity overlies the base layer, with particles bonded to the base layer and to each other to leave interstices therebetween as a repository for retaining and dispensing drugs or other agents for time release therefrom. The particles are composed primarily of a noble metal. Exposed surfaces of the particle layer are coated with ceramic-like iridium oxide or titanium nitrate, as a biocompatible material to inhibit irritation of tissue at the inner lining of the vessel when the stent is implanted.

BACKGROUND OF THE INVENTION

The present invention relates generally to stents which are implantable or deployable in a vascular or endoluminal location within the body of a patient to maintain the lumen open at the implant site, and more particularly to improvements in stent coatings.

Stents are expandable prostheses employed to maintain narrow vascular and endoluminal ducts or tracts of the human body open and unoccluded, such as a portion of the lumen of a coronary artery after dilatation of the artery by balloon angioplasty, for example. In the exemplary case of an occluded coronary artery, the original blockage typically arises from a buildup of fatty deposits or plaque on the inner lining of the vessel. The balloon angioplasty procedure is used to compress the deposits against the inner lining of the vessel, or virtually entire removal may be achieved using other types of angioplasty such as laser or rotational cutting. A different mechanism, however, may cause a new blockage after the angioplasty procedure is performed. The blood vessel wall is subjected to trauma by the balloon, laser or rotating knife, as the case may be, which results in intimal hyperplasia, i.e., a rapid proliferation of smooth muscle cells in the affected region of the wall, to cause restenosis and re-occlusion of the vessel lumen in a significant percentage of angioplasty patients within a period of from three to six months following the initial procedure.

To avoid this re-occlusion and to maintain the lumen of the vessel open, it is now customary procedure to install a stent at the site in the vessel where the angioplasty was performed. The stent is deployed by radial expansion under pressure exerted, for example, by active inflation of a balloon of a balloon catheter on which the stent is mounted, or in some instances by passive spring characteristics of a pre-formed elastic stent, to engage the inner lining or inwardly facing surface of the vessel wall with sufficient resilience to allow some contraction but also with sufficient stiffness to resist to a great degree the natural recoil of the vessel wall that follows its expansion.

The stent itself, however, offers a surface that can promote thrombus formation as blood flows through the vessel. This can result in an acute blockage, which, in a coronary artery, is sufficient to produce an infarction. The thrombosis and clotting can be reduced or even eliminated by localized application of appropriate drugs in a biodegradable formulation, which act for only a period of time sufficient to stave off the thrombus reaction to the presence of the stent in the bloodstream. Some difficulty is encountered in providing a stent surface which is suitable for retention of the necessary drug(s) to achieve those purposes.

A similar situation is encountered at the outward facing surface of the stent that contacts and engages the inner lining of the vessel, duct or tract, where tissue irritation can exacerbate fibrosis of the vessel wall and restenosis in the region of the irritation. Here, also, it would be desirable to provide the stent with the capability to provide a timed release of suitable drug(s) from a biodegradable carrier on or in the affected stent surface, to reduce the occurrence of fibrosis and hyperplasia at the portion(s) of the vessel wall contacted by the stent.

An additional need encountered for stent usage in the human body include a capability to clearly visualize the stent as it is being implanted at the preselected site in the body, as by advancement on a stent delivery system through a portion of the patient's vascular system and into a coronary artery, and after the stent is implanted, for purposes of its examination from time to time at the implant site.

Among the most important features of a suitable stent are the following. The device should be flexible, and yet possess sufficient mechanical strength to resist vessel recoil. It should demonstrate a high rate of successful interventional placement, be highly visible on x-ray fluoroscopy, be very thin to minimize obstruction by its mere presence in the lumen intended to be dilated and held open, and not be an agent which promotes a re-narrowing or re-occlusion of the vessel or duct lumen in which it is implanted. Stent design, of course, can play a major role in influencing the aforementioned features, but also significant is the material(s) of which the stent is composed, with respect to visibility, flexibility, and recoil-resistant characteristics of the stent, as well as its surface characteristics that affect capability of the stent to prevent or inhibit thrombus formation and restenosis in a blood vessel in which the stent is implanted. Current stents have not proved to be capable of fulfilling all of these requirements.

Therefore, it is a principal aim of the present invention to provide a stent which has a composition that offers an enhanced capability to fulfill these important requirements.

SUMMARY OF THE INVENTION

A stent is adapted for deployment in a blood vessel of a human body to maintain the lumen of the vessel open for adequate flow of blood therethrough in the region in which the stent is deployed. The stent has the basic form of an open-ended tubular element with openings through a side thereof, which is adapted to be expanded from a first outside diameter, which is sufficiently small to allow the stent and its delivery system to traverse the vascular system of the human body to reach a site in the blood vessel at which the stent is to be deployed, to a second outside diameter sufficiently large to engage the inner lining of the vessel for retention at the site.

According to a preferred embodiment of the invention, the tubular element or sidewall of the stent includes a first solid layer or thickness of a biocompatible metal, and a second porous layer or thickness which is composed of spherically-shaped metal particles bonded together to leave spaces between the particles. The metal particles are composed at least in part of a noble metal, and specifically, of a platinum-iridium alloy. The spaces between the particles advantageously provide a repository for drugs to assist in maintaining the lumen of the vessel open. The second thickness overlies the first thickness in tightly adherent relation thereto, and has a radiopacity which substantially exceeds that of the first thickness, to provide a highly visible view of the stent by x-ray fluoroscopy during its advancement and deployment in the blood vessel, and thereafter whenever the stent is to be examined in place.

The stent includes at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs, residing in the repository. A biodegradable carrier may be used to retain the drugs for timed release thereof from the repository when the stent is deployed at the selected implant site in the blood vessel. Alternatively, the mere spacing of the metal particles may advantageously provide a timed release of the drugs from the repository. Preferably, for that purpose the particles, which are sized in a range of diameters, are located with the larger diameter sizes adjacent and bonded to the surface of the first thickness and with those and progressively smaller diameter sizes bonded together up to the outermost region of the second thickness. In either event, the anti-platelet and/or anti-thrombotic drugs are preferably infused into the porous layer repository, i.e., into the spaces or interstices between the particles, existing at the inward facing surface (and if desired, at directly adjacent edges of the openings) of the stent to inhibit clogging of the lumen as a result of interaction between the stent itself and the blood flow therethrough. Similarly, the anti-inflammatory and/or anti-proliferative drugs are preferably infused into the repository existing at the outward facing surface (and if desired, at directly adjacent edges of the openings) of the stent to inhibit restenosis as a result of fibrosis or proliferation of tissue from trauma to the inner lining of the vessel arising from contact with the stent.

According to another important feature of the invention, a third layer or thickness of a ceramic-like material—specifically, either iridium oxide or titanium nitrate—is applied as a coating overlying exposed surfaces of the metal particles in tightly adherent relation to the second thickness at those surfaces, without filling or blocking the spaces between the particles, so that the repository for drugs originally formed in the second thickness remains available. Consequently, the desired drugs may be infused into the spaces between particles, in preferential locations as noted above, for retention and dispensing in the same manner as if the third thickness had not been applied. Additionally, the ceramic-like material is resistant to tissue irritation to further avoid such traumatic response during contact of the stent with the inner lining of the vessel at the site.

In a method of fabricating such a multi-layer vascular or endoluminal stent, a porous layer of substantially spherical metal particles is applied atop surfaces of a base metal of the stent, the metal particles at the base metal surfaces being bonded thereto and the metal particles throughout the porous layer being bonded together, with voids therebetween forming a reservoir for retention and dispensing of drugs from the stent when deployed in its vascular or endoluminal location. The metal particles exhibit a radiopacity that substantially exceeds the radiopacity of the base metal for high visibility viewing of the stent by fluoroscopy when advanced and deployed in the body. After applying the porous layer, the exposed surfaces of the metal particles are coated with ceramic-like material consisting of iridium oxide or titanium nitrate while leaving the voids between the particles unblocked and substantially intact so that the reservoir remains available for infusing drugs therein.

The base metal may, for example, be 316L stainless steel, chromium, nickel, titanium, or iridium, or nitinol which is a shape memory nickel-titanium alloy, nominally of 70 micrometers or microns (μm) thickness. The metal particles of platinum-iridium alloy preferably have diameters ranging from about 50 to 500 nanometers, and the porous layer is applied atop the base metal to a thickness in a range from approximately 4 to 8 microns. The iridium oxide or titanium nitrate is coated on surfaces of the metal particles to a thickness in a range from approximately 50 to 500 nanometers. Thereafter, following steps of rinsing, cleaning and drying, the desired drugs or other selected agents are infused into the reservoir provided by the voids or interstices between particles of the porous layer. Timed release of the drugs may be achieved by incorporating them in a biodegradable carrier.

Gene transfer may alternatively be used to inhibit proliferation of smooth muscle cells, to prevent restenosis that could block the lumen of the vessel in which the stent is deployed. In this technique, a viral vector transfers at least part of the genetic information of interest to the target cell. A gene transfer agent constituting the viral vector or virus is incorporated in a biodegradable carrier, or microspheres or liposomes as the viral vector are contained in solution, and the combination is infused into the reservoir of the multi-layer stent from which it is released in a substantially programmed manner to effect the gene transfer.

As will be recognized from considering the detailed description below, a highly important aim of the invention resides in providing a basic structure of a stent which includes three fundamental layers, a first underlying layer constituting a base metal that functions to provide mechanical strength and flexibility, a second intermediate layer that functions to provide high fluoroscopic visibility—preferably a noble metal layer, and most preferably a principally platinum layer in which platinum is in an alloy with a small percentage (about 2%) of iridium—, and a top layer of particularly beneficial biocompatible material—preferably iridium oxide or titanium nitrate. Although the preferred embodiment utilizes a porous intermediate layer, and a remaining porous structure even after formation of the final biocompatible layer, in its most fundamental character the invention contemplates the use of a completely solid intermediate layer to provide the high visibility property and a highly suitable surface for strong bonding of the final coating. The latter itself offers a surface for attachment of the drug/agent-containing carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and still further aims, objects, features, aspects and attendant advantages of the present invention will be better understood from the detailed description below of the best mode presently contemplated of practicing the invention, with reference to the accompanying drawings, in which:

FIG. 1 is a partial perspective view of a basic form of vascular or endoluminal stent, incorporating a multi-layer structure according to the invention;

FIG. 2 is an exaggerated fragmentary cross-sectional detailed view of a portion of the multi-layer structure of the stent of FIG. 1, through the line 2-2 thereof; and

FIG. 3 is a flow chart diagram illustrating the steps of a basic process for fabricating a multi-layer stent of the type illustrated in FIGS. 1 and 2.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT AND METHOD

In FIGS. 1 and 2 (the drawings are not intended to be to scale), a stent 10 may be of generally conventional configuration, with cylindrical structure having open ends, and of any known type such as the Palmaz-Schatz zig-zag tube type shown, or a mesh type, for example. The material of which the metal member 12 of the stent is composed, i.e., the wire or the solid tube, may be of any conventional and suitable type, such as medical grade 316L stainless steel, chromium, nickel, titanium, iridium or nitinol, for example, which is biologically compatible (biocompatible) with the fluids and tissue of the human body. In any event, the sidewall 15 of member 12 is provided with a multiplicity of openings 16 that extend entirely through the wall. For the mesh type stent, the openings are formed as a natural part of the formation of the mesh itself. If the stent is a helical spring-type of structure, the openings are simply the continuous winding space between the coils. For a solid tube type of starting member, openings may be cut in any conventional manner, such as by use of a cutting laser beam operating according to a computer-generated pattern. In the latter instance, care must be exercised to prevent the far side (relative to the position of the laser) of the tube from being cut at the same time that the near side cutting pattern is being produced.

The openings 16 are sized in a conventional manner to assure that body fluids (including blood, in the case of a vascular stent) can contact much of the tissue of the inner lining of the wall of a vessel, duct or tract of the human body in which the stent is to be implanted. For vascular stents, it is also important that side branches of vessels should remain open to the main branch of a vessel in which the stent is deployed. Considerations of stent expansion in a relatively symmetrical manner, and the presence of sufficient thickness of metal to provide enough rigidity to resist collapse as the vessel wall exerts its inward pressure during natural recoil when the stent is fully deployed, also play a significant role in determining the size and number of the sidewall openings, as well as the thickness and final configuration of the member 12 itself.

For implantation in a coronary artery, for example, the production diameter (outer diameter) of the stent 10 may be in a range from about 1.5 millimeters (mm) to 2.0 mm. In any event, the production diameter (or subsequent compressed diameter) constitutes a first diameter which is sufficiently small to allow the stent to be inserted into the vessel, duct or tract of the body in which it is being used, and to be advanced to the site at which it is to be deployed. At that point, the stent is deployed by inflation of the balloon on which it is mounted to radially expand the diameter to a second diameter which is at least slightly larger than the diameter of the lumen of the vessel, duct or tract at that point. In FIG. 1, the stent 10 is illustrated as being partially expanded on its balloon catheter, for the sake of clarity. It is common practice to pre-mount a stent on a balloon 20 of a balloon catheter 23 (partially shown in the Figure) of the stent delivery system, and to supply the combination in a sterile package for convenience of ready use by the implanting physician. Alternatively, the stent could be mounted on the balloon by the physician at the time the procedure is to be performed. If the stent is to be deployed by passive spring characteristics as in the case of a pre-formed elastic stent, the delivery system need not include a balloon.

Again using coronary artery implantation as an example, the mounted stent is inserted into the patient's vascular system (not shown) at an appropriate location, and is then advanced on the balloon catheter to the selected site. The path of the stent to the site of deployment as well as identification of the target site in the coronary artery are viewed and determined by fluoroscopy. When properly located at the target site, the balloon 20 is inflated by introducing a fluid through an inflation lumen of the catheter to radially expand the stent diameter to an extent that the stent will engage and exert at least slight pressure on the inner lining of the vessel wall. When the stent is fully deployed, the balloon is deflated and the catheter 23 is withdrawn from the patient's vascular system and body. The stent 10 should possess sufficient rigidity in the fully deployed expanded state to prevent it from collapsing under the radially directed inward pressure exerted by the artery wall from natural recoil thereof as the balloon is deflated.

When crimped onto the mounting balloon, the coronary artery stent outer diameter will typically lie in a range from about 0.9 to about 1.2 mm, with an inner diameter in a range from about 0.6 to about 0.7 mm. The inner diameter of the stent when fully deployed to the expanded diameter at the target site will typically lie in a range from about 2.5 to about 6.0 mm. The final deployed diameter should be a size which will assure that the stent is retained in place, firmly engaged with the inner lining of the artery wall.

For other vascular sites such as the renal artery, the carotid or femoral artery, or the ductus hepaticus in the liver, a diameter of approximately 4.0 to 8.0 mm is appropriate. This stent size range is produced from tubing of one of the aforementioned core metal materials, typically 316L stainless steel, of 3.2 mm outside diameter and arranged and adapted to be expanded (opened) to a larger outside diameter by cutting a predetermined pattern of openings through the sidewall of the stent. For applications in the bronchial location or in the vascular iliac location, a principal size range of from 8.0 to 12.0 mm outside diameter, fully opened, is desired. For esophageal applications in patients with malignant narrowing of the esophagus lumen, a range of diameter sizes from about 12.0 to 18.0 mm is adequate.

A stent 10 fabricated according to the present invention is composed of three different primary or fundamental layers as shown in the greatly exaggerated fragmentary cross-sectional view of FIG. 2, taken through the line 2-2 of FIG. 1. By “primary” and “fundamental”, as used here, it is meant and intended that although the stent may have additional layers, coatings or films, the three layers to be described below are essential to the favorable characteristics enjoyed by the stent.

The base layer 30 of the tubular member 12 of stent 10 is a biocompatible metal or an alloy of metals which has been or can be demonstrated to be suitable for implantation in the human body. Each of the other layers of the multi-layer structure of the stent is also biocompatible but that feature is not necessarily its primary characteristic, as well be understood from the description below. Focusing on the base layer or core material thickness 30 of the stent, materials such as 316L stainless steel, or nickel-titanium alloy known as nitinol which has a shape memory property, among others, are popular in medical implants and possess favorable characteristics of elasticity, mechanical strength and fatigue. The mechanical strength must be adequate to resist recoil of the vessel wall and to provide a scaffold that maintains an adequate lumen opening for the vessel being stented. Stent deployment may be achieved by active balloon inflation, or by passive spring opening attributable to pre-formed elasticity of the stent base material. These results are typically achievable with very thin-walled stents, in a range from 60 to 80 micrometers or microns (.mu.m) thick. However, the customary materials and material thicknesses are inadequate for sufficient visibility under fluoroscopic x-ray implantation or examination. In practice, this means that identifying the stent for deployment at the precise target site might be difficult, especially if the stent delivery system (e.g., a balloon catheter such as 23 in FIG. 1, in the case of active deployment) were not provided with radiopaque markers, and, that after implantation, greater difficulty may be encountered in attempting to locate the exact site of the stent for periodic examination, the advantage of the markers associated with the stent delivery system having been lost when the latter was withdrawn.

The atomic number (Z) of the base material may be about 28, in the case of medical grade stainless steel or nitinol, compared to Z=7.2 for the human body. To increase the visibility of a stent composed of such material under x-ray fluoroscopy, it is common practice to fabricate the stent tube to have a thickness of about 150 μm, which, however, results in an undesirable loss of lumen diameter of the vessel when the stent is implanted therein. Reducing the thickness of the stent by about half, to 75 μm, would result in a gain in lumen diameter of 150 μm (2×75 μm, or about 5% of the total lumen of a 3 millimeter (mm) vessel such as a coronary artery. Since the primary function of the stent is to maintain an unobstructed lumen in the vessel in which it is implanted, it is desirable, to the extent practicable, to avoid obstruction attributable to the mere thickness of the stent itself. Also, in general, the stiffness of a stent increases directly with the thickness of the material of which it is composed. Stent stiffness increases the order of difficulty of implanting the stent, which is another reason for finding ways to reduce thickness without seriously affecting mechanical strength and radiopacity of the stent.

In fabricating the stent 10, the base material 30 such as 316L stainless steel is formed into an open-ended tubular structure of approximately 70 μm thickness, for example, and of selected appropriate length. Openings are cut (in the case of a tubular member with a solid wall, in contrast to a mesh or spring wound type) in a predetermined pattern through its sidewall, as by laser cutting, for example. This allows the stent diameter to be expanded (opened, e.g., during deployment) from a selected production diameter which will depend on the inner diameter of the vessel or duct in which the stent is to be inserted and advanced to a selected site of implantation. After openings are provide in the sidewall of the tubular member, it is subjected to customary cleaning and polishing steps. All exposed surfaces of the stent, including the outward and inward facing surfaces, the edges of the through holes in the sidewall, and the ends of the sidewall, should be left at least slightly roughened, as by incomplete electro-polishing or by abrasion or by acid washing, or the like, to enhance adhesion of the next layer. Similar steps are followed if a shape memory or spring memory material is used, such as nitinol, although the stent itself in such a case might instead have a helical rather than a tubular configuration, which would eliminate the need for additional openings through a sidewall.

The next layer, which is to be applied atop the base metal layer 30, is intended to serve multiple purposes. In the preferred embodiment, this second, middle or intermediate layer 32 (again, these terms being used without limitation of the overall stent to only three layers or an absence of intervening layers) is preferably composed of a multiplicity of microspherical particles, or microspheres 33, of suitable metal or alloy, ranging in size (diameter) from about 50 to 500 nanometers (nm) and applied to form a layer thickness in a range from about 4 to about 8 μm, preferably nominally about 5 μm, atop the exposed surfaces of the sidewall constituted by base layer 30. The microspheres are built up on the surface of the tube in a manner such that the bottom or lowermost portion of the layer consists of microspheres adherent to the tube surface, and intervening portions up to the top or uppermost portion of this layer consist of microspheres connected or bonded (adherent) to one or more adjacent microspheres at points of tangency or near tangency (e.g., 35) therebetween. This configuration is such that voids or open spaces 37 are present throughout the layer, as interstices between adjacent microspheres. Thus, the intermediate layer may be characterized as being porous, and this is important for a purpose which will be discussed in detail presently.

To render the stent more radiopaque despite the relative thinness of the base layer (here, the tube sidewall) 30 as compared to prior or current stent configurations, the intermediate layer 32 is preferably composed of a noble metal, most preferably platinum. Platinum has an atomic number (Z=77) almost three times that of steel, and therefore provides a highly radiopaque presence even though the overall dimension of this layer is very thin. To provide increased hardness, the platinum is preferably incorporated in an alloy with iridium, the latter in a percentage by overall weight in a range from about 2% to about 10%, preferably at or near the lower end of the range. The presence of iridium, which is of similar atomic number to platinum (Z=78), does not detract from the enhanced radiopacity of the intermediate layer 32. If a nitinol base layer is utilized rather than stainless steel or other medical implant-grade material, the iridium serves to improve the match between the physical characteristics of the nitinol layer and the intermediate layer.

The process by which the intermediate layer is applied preferably employs powder metallurgy. In addition to its other significant attributes, the surface tension and friction characteristic of the product to this point is improved over a stent having an ultra smooth surface. In the process, the particulate or powder metal is applied to the base layer surface and tightly bonded thereto, and built up to the desired layer thickness of high porosity by forming an interconnected multiplicity of the particles (microspheres), through application of heat. Suitable powder metallurgy processing for this material has been developed by Hittman Materials & Medical Components, Inc. of Columbia, Md.

The interstices 37 constituting the spaces or voids between the spherical platinum-iridium particles 33 are sufficiently sized and plentiful as a result of the formation of layer 32, to provide in overall effect a reservoir or repository for the infusion and retention of drugs which are beneficial or an aid to the use of the stent when implanted in a particular vessel or duct, such as in a coronary artery or other blood vessel. So the intermediate layer 32 provides not only the benefits of increased radiopacity of the stent, but also enables retention of drugs which may be released over time from the surface of the stent to enhance or inhibit certain functions.

For example, when the stent is intended for deployment at a selected site to support the inner lining of a coronary artery which has undergone an angioplasty procedure, to maintain the lumen thereof open, the outward facing surface of the stent and at least part of the edges of the openings adjacent thereto in the stent will ultimately be placed in contact and engagement with tissue of the inner lining of the artery wall. In contrast, the inward facing surface forms the lumen of the stent, and portions of the edges of the openings 16 (in the multi-layer final structure) will be contacted by blood flowing through the artery (and thereby, through the lumen of the implanted stent).

Therefore, the voids or pores 37 in the outward facing surface and adjacent edge surfaces of intermediate layer 32 are advantageously used in total as a repository for drugs formulated to inhibit inflammation or proliferation of tissue from trauma of the stent engagement or related mechanism—drugs such as dexamethasone or taxol, respectively, or both. The spaces between particles in the inward facing surface and adjacent edge surface of intermediate layer 32 are, on the other hand, suitable for use as a repository of drugs to inhibit thrombus or platelet formation attributable to presence of the stent in the bloodstream—drugs such as hirudin or iloprost, respectively, or both.

Before depositing or infusing any such selected drugs in the voids 37 between particles 33, however, a third layer or coating 40 may be and preferably is formed on the exposed surface(s) of the intermediate highly porous layer 32 of interconnected spherical platinum-iridium particles 33. This third or upper or outermost or superficial layer 40 is preferably composed of either iridium oxide (IROX) or titanium nitrate. Each of these materials is in the nature of a ceramic, i.e., is ceramic-like, and although either one of them is preferred for this embodiment, each is exemplary of a biocompatible layer that serves a primary purpose of avoiding tissue irritation and thrombus formation. This outermost layer may be deposited as an inert coating over the surface(s) of the underlying intermediate layer 32 by any known method, preferably to a thickness in the range from about 10 to 500 nanometers (nm), preferably nominally 200 nm.

Layer 40 need not and preferably does not fully coat all surfaces in the interstices of the porous intermediate layer 32, but need merely cover the more exposed surfaces of particles 33 of that underlying layer, so that when the completed stent is ultimately deployed it is this outer coating 40 that principally if not solely contacts the inner lining of the vessel and the blood flowing through the lumen of the vessel. As shown in FIG. 2, these are primarily the top surfaces of the uppermost spheres of intermediate layer 32. Hence, a sputtering process is adequate for providing the coating, and more desirable than a process that would include immersion of the stent as fabricated to this point in a solution of iridium where more extensive surface coverage is desired, in the case of iridium oxide. Here again, suitable processes have been developed and can be performed by Hittman Materials & Medical Components, Inc., for example. It is, of course, desirable that porous underlayer 32 be left with its voids 37 intact, i.e., not filled or substantially blocked with iridium oxide or titanium nitrate, so that the reservoir or repository remains available after application of coating 40, for infusion and retention of beneficial drugs.

The intermediate porous layer 32 also serves the purpose of providing, a suitable underlayer, along with base layer 30, to allow flexing of the stent over a vast number of cycles encountered in actual use without loss of the overlying iridium oxide or titanium nitrate coating from flaking, shedding or disintegration. After the outermost layer 40 is formed (or upon completion of the spherical platinum-iridium particulate layer 32, if only that layer is to be applied atop the base layer to essentially complete the stent), including such cleaning, rinsing and drying as is necessary to complete the process, the desired anti-inflammatory and/or anti-proliferation drugs are applied to enter the interstices of the porous medium constituting the outward facing surface and adjacent edges of openings of the stent. The desired anti-thrombotic and/or anti-platelet agents are applied to enter the interstices at the inward facing surface and adjacent edges of openings of the stent. By virtue of the very nature of this repository, the drugs or agents are, to an extent, time released therefrom to provide a primarily acute response to tissue trauma and clotting mechanisms.

The drug release response may be more carefully controlled by fabricating the intermediate layer 32 in a manner to position the larger spheres of the platinum-iridium particulate matter 33 directly adjacent and bonded to the base layer surface, and increasingly smaller-sized particles as the uppermost region of the layer is approached, as represented in the showing of FIG. 2. This has the effect of increasing the size of the spaces 37 between particles at the bottom, and, thus, provides a larger reservoir or repository there, and of reducing the voids as the uppermost or outermost region is approached, whereby to reduce the spaces and reservoir volume in that region.

Additionally, or alternatively, the timed release of the beneficial drugs from the interstices of the porous layer 32 may be controlled by incorporating the drugs in a biodegradable carrier, preferably of a type described in the applicant's U.S. patent application Ser. No. 08/798,333. This carrier that contains the drugs or other applicable agents is represented at 43, by way of example, in the fragmentary exaggerated cross-section of FIG. 2. The time-controlled release in this case is attributable to the degradation or disintegration of the carrier itself, so that the drug or other agent remains captive within the carrier until it is dispensed or released, i.e., freed from its host, by progressive dissolution upon continuing diffusion of the carrier from the reservoir.

As an alternative to the infusion or incorporation of anti-proliferative or anti-inflammatory drugs into the reservoir along the outward facing porous structure of the intermediate layer, which is substantially retained and available after application of the non-filling, non-blocking final biocompatible coating, gene transfer may be used to inhibit the smooth muscle cell growth that leads to neointima and restenosis. In principle, a viral vector is used to transfer the desired information into the genome of the target cells. Viruses capable of such gene transfer are, for example, adenovirus and herpervirus, or fractions of the virus. By viral transfer, which is believed to occur by virtue of absorption and diffusion, part of the genetic information of interest is provided to the target cell. Such information can relate to several mechanisms of smooth muscle cell proliferation, with the aim of inhibiting restenosis which, if unchecked, could result in at least partial and perhaps complete blockage of the vessel's lumen, despite the presence of the deployed stent at the site.

One important technique involves blocking the proliferation stimulating factors such as cytoKines, n Fkappa b, platelet derived growth factors or other growth factors that originate from platelet deposition, thrombus formation, mechanical stress, or injury and inflammation. The applicant herein is currently investigating whether selective inducement of apotosis—or programmed cell death—may be achieved via the fas-ligand, which would enable a programmed intervention against overshooting cellular proliferation in a narrowly controlled region of the tissue.

The virus transfer is performed by incorporating the gene transfer agent—a viral vector or virus of the above-mentioned type that contains the viral genetic information desired to be transferred to the target cell(s)—into a biodegradable carrier, as at 43 of FIG. 2, for release from the reservoir into which it has been infused and dispensed by the process of biodegradation. Alternatively, the release to effect the gene transfer may be accomplished by release from a solution in the reservoir which contains liposomes as the viral vector.

The invention also contemplates the use of an intermediate high visibility layer which is completely solid, rather than porous, between the mechanical strength- and flexibility-providing layer which is the base material of the stent and the uppermost biocompatible layer. Such a solid intermediate layer is also preferably composed of a noble metal, and most preferably a platinum-iridium alloy in which the percentage of iridium is relatively small, e.g., about 2%, and which provides excellent surface characteristics to promote a strong bonding or adherence of the final coating of iridium oxide or titanium nitrate. The intermediate layer here may be applied by a conventional electroplating, for example, or other suitable process, instead of a powder metallurgy technique, for example, by which a porous thickness can be provided. The final coating has a sufficiently rough exposed surface to assure some attachment of a carrier incorporating the aforementioned drugs or other agents therein, albeit not to an extent offered by the reservoir or repository provided by the porous layer of the preferred embodiment. Layer thicknesses are substantially the same as those for the preferred embodiment which utilizes a porous intermediate layer.

The basic process for fabricating a multi-layer stent of the type which has been described herein in conjunction with FIGS. 1 and 2 is illustrated in the flow chart of FIG. 3. First, the basic metal tubular structure 12 with sidewall 30 is prepared or implemented in any conventional manner. The example of starting with a tube having a solid sidewall has already been described earlier in this detailed description. Metal particles 33 are next bonded to the surface of the sidewall or basic layer 30 as well as to themselves to form intermediate porous layer 32, with sufficient voids between the particles therein to constitute a reservoir for retention of beneficial drugs, other agents, or virus vectors for gene transfer. An iridium oxide (or titanium nitrate) coating 40 is then applied to exposed surfaces of the porous layer 32 to provide a biocompatible surface for the overall basic stent. Finally, the drugs, agents and/or vectors to aid in overcoming undesired responses of the tissue and fluids of the body to intervention of the stent, are infused into the interstices 37 together with a biodegradable carrier to fill or partially fill the reservoir from which they are dispensed after the stent is implanted in the body.

Clinical studies required by protocols to obtain regulatory approval for marketing and use of medical devices in the United States generally mandate millions of cycles of flexation indicative of many years of deployment and usage of the stent, representative of the environment of the stent when implanted and in use in the human body.

Although a preferred embodiment and method of fabrication have been disclosed herein, it will be recognized by those of ordinary skill in the art to which the invention pertains, from a consideration of the foregoing description, that variations and modifications may be made without departing from the spirit and scope of the invention. Accordingly, it is intended that the invention shall be limited only by the appended claims and the rules and principles of applicable law. 

1. A vascular or endoluminal stent adapted to be implanted in a selected vessel, duct or tract of a human body to maintain an open lumen at the site of the implant, comprising an open-ended tubular structure having a base layer of metal constituting a sidewall which is biologically compatible with the blood and tissue of the human body, and a metal particulate layer of substantially greater radiopacity than the base layer overlying and composed of particles bonded to the base layer and to each other with interstices therebetween for retention of drugs to be time released therefrom after the stent is implanted, to assist the stent in maintaining said lumen open.
 2. The stent of claim 1, wherein the particles comprise a noble metal.
 3. The stent of claim 2, wherein the noble metal is part of an alloy.
 4. The stent of claim 3, wherein the alloy is platinum-iridium.
 5. The stent of claim 4, wherein the particulate layer has a thickness in a range from about 4 to about 8 μm.
 6. The stent of claim 2, wherein the sidewall has an outward facing surface, an inward facing surface, and edges along holes through the sidewall and the open ends thereof, and the particles and said interstices therebetween are present along at least one of said outward facing surface and said inward facing surface.
 7. The stent of claim 6, wherein the particles are of substantially spherical shape with larger particle spheres bonded to the at least one surface and progressively smaller spheres are present from and bonded to the larger particle spheres and to each other up to the surface of the metal particulate layer.
 8. The stent of claim 6, wherein the particle spheres and the interstices therebetween are present along each surface and the edges of the openings and open ends of the sidewall.
 9. The stent of claim 6, wherein the particle spheres range in diameter from about 50 to about 500 nanometers, and the metal particulate layer is in a range of thickness from about 4 to about 8 μm.
 10. The stent of claim 1, wherein at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs is present in said interstices.
 11. The stent of claim 10, wherein said at least one drug is incorporated in a biodegradable material for time release of the drug.
 12. The stent of claim 1, wherein a viral vector is inserted into said interstices and selected for transfer of genetic information to target cells in tissue at the inner lining of said vessel, duct or tract to inhibit proliferation of tissue growth threat.
 13. The stent of claim 12, wherein said viral vector is incorporated in a biodegradable material.
 14. The stent of claim 8, wherein an anti-thrombotic drug is present in said interstices along the inward facing surface, and an anti-inflammatory drug is present in said interstices along the outward facing surface.
 15. The stent of claim 14, wherein said drugs are incorporated in a biodegradable material for timed release thereof from the interstices when said stent is implanted.
 16. The stent of claim 1, wherein exposed surfaces of the metal particulate layer are coated with a ceramic-like material to inhibit irritation to tissue at the inner lining of said vessel, duct or tract when the stent is implanted therein in contact with said inner lining.
 17. The stent of claim 16, wherein said ceramic-like material is selected from a group consisting of iridium oxide or titanium nitrate.
 18. The stent of claim 17, wherein the ceramic like material is coated to a thickness in a range from approximately 50 to 500 nanometers.
 19. The stent of claim 17, wherein the ceramic-like material coating is of insufficient thickness to fill or substantially block said interstices, and at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs is present in said interstices.
 20. The stent of claim 19, wherein said at least one drug is incorporated in a biodegradable material for tie release of the drug.
 21. The stent of claim 17, wherein the ceramic-like material coating is of insufficient thickness to fill or substantially block said interstices, and wherein a viral vector residing in said interstices is selected for transfer of genetic information to target cells in tissue at the inner lining of said vessel, duct or tract to inhibit proliferation of tissue growth threat.
 22. The stent of claim 4, wherein exposed surfaces of the platinum-iridium alloy particles of said metal particulate layer are coated with a ceramic-like material to inhibit irritation to tissue at the inner lining of said vessel, duct or tract when the stent is implanted therein in contact with said inner lining.
 23. The stent of claim 4, wherein exposed surfaces of the platinum-iridium alloy particles of said metal particulate layer are coated with a ceramic-like material to inhibit irritation to tissue at the inner lining of said vessel, duct or tract when the stent is implanted therein in contact with said inner lining.
 24. The stent of claim 23, wherein said ceramic-like material is selected from a group consisting of iridium oxide or titanium nitrate.
 25. The stent of claim 24, wherein the ceramic-like material costing is of insufficient thickness to fill or substantially block said interstices, and at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs is present in said interstices.
 26. The stent of claim 25, wherein said at least one drug is incorporated in a biodegradable material for time release thereof when the stent is implanted.
 27. The stent of claim 24, wherein the ceramic-like material coating is of insufficient thickness to fill or substantially block said interstices, and wherein a viral vector is inserted into said interstices and selected for transfer of genetic information to target cells in tissue at the inner lining of said vessel, duct or tract to inhibit proliferation of tissue growth threat.
 28. The stent of claim 27, wherein said viral vector is incorporated in a biodegradable material.
 29. The stent of claim 25, wherein the particles of the metal particulate layer are bonded together in a pattern such that the interstices therebetween produce a timed release of a drug present therein when the stent is implanted.
 30. The stent of claim 8, wherein exposed surfaces of the metal particulate layer are coated with a ceramic-like material to inhibit irritation to tissue at the inner lining of said vessel, duct or tract when the stent is implanted therein in contact with said inner lining.
 31. The stent of claim 30, wherein said ceramic-like material is selected from a group consisting of iridium or titanium nitrate.
 32. The stent of claim 31, wherein the ceramic-like material coating is of insufficient thickness to fill or substantially block said interstices, and at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs is present in said interstices.
 33. The stent of claim 32, wherein an anti-thrombotic drug is contained in said interstices along the inward facing surface, and an anti-inflammatory drug is contained in said interstices along the outward facing surface.
 34. The stent of claim 33, wherein said drugs are incorporated in a biodegradable carrier for time release thereof from the interstices when said stent is implanted.
 35. The stent of claim 34, wherein the particles of the metal particulate layer are bonded together in a pattern such that the interstices therebetween produce a timed release of a drug present therein when the stent is implanted.
 36. A stent for deployment in a blood vessel of a human body to maintain the lumen of the vessel open for adequate flow of blood therethrough in a region of the vessel in which the stent is deployed, the stent comprising an open-ended tubular element having openings through a side thereof and adapted to be expanded from a first outside diameter sufficiently small to traverse the vascular system of the human body to a site in the blood vessel at which the stent is to be deployed, to a second outside diameter sufficiently large to engage the inner lining of the vessel at said site for retention thereat, said side including a first solid thickness of a biocompatible metal and a second porous thickness comprising metal particles bonded together with spaces between the particles, said second thickness overlying the first thickness and in tightly adherent relating thereto and having a radiopacity that substantially exceeds that of the first thickness for high visibility viewing of the stent by x-ray fluoroscopy when deployed in the blood vessel, the spaces between the particles providing a repository for drugs to assist in maintaining said open lumen.
 37. The stent of claim 36, wherein said metal particles are composed at least in part of a noble metal.
 38. The stent of claim 36, wherein said metal particles are composed of a platinum-iridium alloy.
 39. The stent of claim 36, further including at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs, present in said repository.
 40. The stent of claim 39, further including a biodegradable carrier incorporating said at least one drug in said repository, for timed release of the drug therefrom when the stent is deployed at said site in the blood vessel.
 41. The stent of claim 39, wherein the spacing of the metal particles provides a timed release of said at least one drug from the repository, when the stent is deployed at said site in the blood vessel.
 42. The stent of claim 36, further including a viral vector inserted into said repository and selected for transfer of genetic information to target cells in tissue at the inner lining of the blood vessel to inhibit proliferation of tissue growth thereat.
 43. The stent of claim 42, wherein said viral vector is incorporated in a biodegradable material.
 44. The stent of claim 36, further including a third thickness of a ceramic-like material overlying exposed surfaces of the metal particles of the second thickness and in tightly adherent relating thereto without filling or substantially blocking said spaces therebetween, so that a repository for drugs remains available, said ceramic-like material being resistant to tissue irritation for avoidance thereof during contact of the stent with the inner lining of the vessel at said site.
 45. The stent of claim 44, wherein said ceramic-like material is selected from a group consisting of iridium oxide or titanium nitrate.
 46. The stent of claim 38, further including a third thickness of a ceramic-like material selected from a group consisting of iridium oxide or titanium nitrate overlying exposed surfaces of the platinum-iridium alloy particles of the second thickness and in tightly adherent relation thereto without filling or substantially blocking said spaces therebetween, so that a repository for drugs remains available, and at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs, present in said repository.
 47. The stent of claim 46, further including a biodegradable carrier incorporating said at least one drug in the repository, for timed release of the drug therefrom when the stent is deployed at said site in the blood vessel.
 48. The stent of claim 38, further including a third thickness of a ceramic-like material selected from a group consisting of iridium oxide or titanium nitrate overlying exposed surfaces of the platinum iridium alloy particles of the second thickness and in tightly adherent relation thereto without filing or substantially blocking said spaces therebetween, so that a repository for drugs remains available, and further including a viral vector in said repository selected for transfer of genetic information to target cells in the vicinity of the stent when implanted in the blood vessel, to inhibit cellular proliferation thereat.
 49. The stent of claim 48, further including a biodegradable carrier incorporating said viral vector in the repository, for timed release therefrom when the stent is deployed at said site in the blood vessel.
 50. The stent of claim 46, wherein the spacing of the platinum-iridium alloy particles provides a timed release of said at least one drug from the repository, when the stent is deployed at said site in the blood vessel.
 51. The stent of claim 46, wherein the second thickness is in a range from about 4 to 8 microns, the platinum-iridium alloy particles are substantially spherical ranging in diameter from about 50 to 500 nanometers, and said third thickness is in a range from about 50 to 500 nanometers.
 52. A method of fabricating a multi-layer vascular or endoluminal stent for deployment in a human body to hold a natural duct or tract thereof open for passage of fluids or solids therethrough, comprising steps of applying a porous layer of substantially spherical metal particles atop surfaces of a base metal of the stent, said metal particles at the base metal surfaces being bonded thereto and said metal particles throughout the porous layer being bonded together with voids therebetween forming a reservoir for retention and dispensing of drugs from the stent when deployed, said metal particles having a radiopacity that substantially exceeds that of the base metal for high visibility viewing of the stent by fluoroscopy when deployed in the body, and coating exposed surfaces of the metal particles with a ceramic-like material while leaving said voids therebetween substantially intact and unblocked so that said reservoir remains available for infusing drugs therein.
 53. The method of claim 52, wherein the base metal is from a group including stainless steel, chromium, nickel, titanium, iridium, and nickel-titanium alloy.
 54. The method of claim 53, wherein the metal particles are composed of platinum-iridium alloy with diameters ranging from about 50 to 500 nanometers, and the porous layer is applied to a thickness in a range from approximately 4 to 8 microns atop surfaces of the base metal.
 55. The method of claim 54, wherein the ceramic-like material is selected from a group consisting of iridium oxide and titanium nitrate, and is coated on surfaces of the metal particles to a thickness in a range from approximately 50 to 500 nanometers.
 56. The method of claim 55, further including the step of infusing in said reservoir at least one drug selected from a group including anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs.
 57. The method of claim 56, further including infusing a biodegradable carrier for said at least one drug in said reservoir, for timed release of the drug therefrom.
 58. A vascular or endoluminal stent adapted to be implanted in a selected vessel, duct or tract of a human body to maintain an open lumen at the site of the implant, comprising an open-ended tubular structure having a base layer of metal constituting a sidewall which is biologically compatible with the fluids and tissue of the human body, an intermediate layer of substantially greater radiopacity than the base layer overlying and bonded to the base layer, and a ceramic-like material coating on and adherent to exposed surfaces of the intermediate layer to inhibit irritation to tissue at the inner lining of said vessel, duct or tract when the stent is implanted therein in contact with said inner lining.
 59. The stent of claim 58, wherein the intermediate layer comprises a noble metal.
 60. The stent of claim 59, wherein the noble metal is part of an alloy.
 61. The stent of claim 60, wherein the alloy is platinum-iridium.
 62. The stent of claim 61, wherein the intermediate layer has a thickness in a range from about 4 to about μm.
 63. The stent of claim 58, wherein said ceramic-like material is selected from a group consisting of iridium oxide or titanium nitrate.
 64. The stent of claim 62, wherein said ceramic-like material is selected from a group consisting of iridium oxide or titanium nitrate, and is coated to a thickness in a range from approximately 50 to 500 nanometers.
 65. The stent of claim 63, further including at least one drug selected from a group consisting of anti-thrombotic, anti-platelet, anti-inflammatory and anti-proliferative drugs, applied to the ceramic-like material coating.
 66. The stent of claim 65, wherein said at least one drug is incorporated in a biodegradable material for timed release of the drug as the biodegradable material undergoes disintegration when the stent is implanted in a fluid-carrying vessel of the body.
 67. The stent of claim 66, wherein the sidewall has an outward facing surface and an inward facing surface, with holes through the sidewall, and wherein an anti-inflammatory drug is present along the outward facing surface and an anti-thrombotic drug is present along the inward facing surface.
 68. The stent of claim 63, further including a viral vector selected for transfer of genetic information to target cells in the vicinity of the stent when implanted in said vessel, duct or tract to inhibit proliferation thereof, applied to the ceramic-like material coating.
 69. The stent of claim 68, wherein said viral vector is incorporated in a biodegradable material. 